Return to Trial Database

HCRN-MEL16-252

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252

Status

Enrollment Closed

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial HCRN-MEL16-252 being conducted in.

Fox Chase Cancer Center

Masonic Cancer Center, University of Minnesota

Nebraska Cancer Specialists

Providence Cancer Institute

University of Iowa Holden Comprehensive Cancer Center